Accueil   Diary - News   All news Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)

Imaxio signs an option for a license agreement with the German Cancer Research Center (DKFZ)

IMAXIO NEWSLETTER

Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus (HPV)

 

Imaxio, a biopharmaceutical company specialized in vaccines, today announces that it has signed an option for a license agreement with the world-renowned German Center for Cancer Research (DKFZ – Deutsches Krebsforschungszentrum), based in Heidelberg. The financial terms of the agreement were not disclosed.

 

 

Read the press release